Davidson W F, Giese T, Fredrickson T N
Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Exp Med. 1998 Jun 1;187(11):1825-38. doi: 10.1084/jem.187.11.1825.
B cell malignancies arise with increased frequency in aging individuals and in patients with genetic or acquired immunodeficiency (e.g., AIDS) or autoimmune diseases. The mechanisms of lymphomagenesis in these individuals are poorly understood. In this report we investigated the possibility that mutations at the Fas (lpr) and Fasl (gld) loci, which prevent Fas-mediated apoptosis and cause an early onset benign lymphoid hyperplasia and autoimmunity, also predispose mice to malignant lymphomas later in life. Up to 6 mo of age, hyperplasia in lpr and gld mice results from the predominant accumulation of polyclonal T cell subsets and smaller numbers of polyclonal B cells and plasma cells. Here, we examined C3H-lpr, C3H-gld, and BALB-gld mice 6-15 mo of age for the emergence of clonal T and B cell populations and found that a significant proportion of aging mice exclusively developed B cell malignancies with many of the hallmarks of immunodeficiency-associated B lymphomas. By 1 yr of age, approximately 60% of BALB-gld and 30% of C3H-gld mice had monoclonal B cell populations that grew and metastasized in scid recipients but in most cases were rejected by immunocompetent mice. The tumors developed in a milieu greatly enriched for plasma cells, CD23- B cells and immunodeficient memory T cells and variably depleted of B220+ DN T cells. Growth factor-independent cell lines were established from five of the tumors. The majority of the tumors were CD23- and IgH isotype switched and a high proportion was CD5+ and dull Mac-1+. Considering their Ig secretion and morphology in vivo, most tumors were classified as malignant plasmacytoid lymphomas. The delayed development of the gld tumors indicated that genetic defects in addition to the Fas/Fasl mutations were necessary for malignant transformation. Interestingly, none of the tumors showed changes in the genomic organization of c-Myc but many had one or more somatically-acquired MuLV proviral integrations that were transmitted in scid passages and cell lines. Therefore, insertional mutagenesis may be a mechanism for transformation in gld B cells. Our panel of in vivo passaged and in vitro adapted gld lymphomas will be a valuable tool for the future identification of genetic abnormalities associated with B cell transformation in aging and autoimmune mice.
B细胞恶性肿瘤在老年人以及患有遗传性或获得性免疫缺陷(如艾滋病)或自身免疫性疾病的患者中出现的频率增加。这些个体中淋巴瘤发生的机制尚不清楚。在本报告中,我们研究了Fas(lpr)和Fasl(gld)基因座发生突变的可能性,这些突变可阻止Fas介导的细胞凋亡并导致早期良性淋巴样增生和自身免疫,同时也使小鼠在生命后期易患恶性淋巴瘤。在6个月龄之前,lpr和gld小鼠的增生是由于多克隆T细胞亚群的主要积累以及数量较少的多克隆B细胞和浆细胞。在此,我们检查了6至15个月龄的C3H-lpr、C3H-gld和BALB-gld小鼠中克隆性T和B细胞群体的出现情况,发现相当比例的老龄小鼠仅发生了具有免疫缺陷相关B淋巴瘤许多特征的B细胞恶性肿瘤。到1岁时,大约60%的BALB-gld和30%的C3H-gld小鼠具有单克隆B细胞群体,这些群体在scid受体中生长并转移,但在大多数情况下被免疫 competent小鼠排斥。肿瘤在富含浆细胞、CD23 - B细胞和免疫缺陷记忆T细胞且B220 + DN T细胞可变减少的环境中发生。从其中五个肿瘤中建立了不依赖生长因子的细胞系。大多数肿瘤为CD23 - 且IgH同种型转换,高比例为CD5 + 且Mac-1 + 暗淡。考虑到它们在体内的Ig分泌和形态,大多数肿瘤被分类为恶性浆细胞样淋巴瘤。gld肿瘤的延迟发生表明除了Fas/Fasl突变外,还需要其他遗传缺陷才能发生恶性转化。有趣的是,没有一个肿瘤显示c-Myc基因组组织发生变化,但许多肿瘤有一个或多个体细胞获得的MuLV前病毒整合,这些整合在scid传代和细胞系中得以传递。因此,插入诱变可能是gld B细胞转化的一种机制。我们的体内传代和体外适应的gld淋巴瘤 panel将成为未来鉴定与衰老和自身免疫小鼠B细胞转化相关的遗传异常的有价值工具。